title: CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
abstract: The study included 52 patients at a high risk of thromboembolic complications, with permanent atrial fibrillation. All patients were treated with acenocoumarol for 6 months and the incidence of hemorrhages was evaluated in all of them. All patients were genotyped by CYP2C9 and VKORC1. The presence of CYP2C9*2 and CYP2C9*3 alleles of CYP2C9 locus and AA genotype of VCORC1 gene polymorphic G-1639(3673)A marker was not associated with the development of hemorrhages under conditions of acenocoumarol treatment (p=0.144 for CYP2C9, p=0.809 and 0.918 for VCORC1 in the total group and subgroup of patients with CYP2C9*1/*1 genotype, respectively). The search for other genetic markers of acenocoumarol efficiency and safety is needed for predicting the risk of hemorrhages during this treatment.
authors.affiliation: Clinical Pharmacology Affiliated Department of Research Center of Biomedical Technologies, Russian Academy of Medical Sciences, Moscow, Russia. dmitry.alex.sychev@gmail.com
authors.forename: D V
authors.initials: DV
authors.lastname: Sychev
authors.forename: I V
authors.initials: IV
authors.lastname: Ignatyev
authors.forename: N V
authors.initials: NV
authors.lastname: Emelyanov
authors.forename: V V
authors.initials: VV
authors.lastname: Milovanova
authors.forename: A V
authors.initials: AV
authors.lastname: Kossovskaya
authors.forename: I V
authors.initials: IV
authors.lastname: Kukes
authors.forename: A I
authors.initials: AI
authors.lastname: Tashenova
authors.forename: V G
authors.initials: VG
authors.lastname: Kukes
mesh_terms: D000074:Acenocoumarol / Q000009:adverse effects*; D000483:Alleles; D000925:Anticoagulants / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D056426:Genetic Loci; D005838:Genotype; D060005:Genotyping Techniques; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D012306:Risk; D012426:Russia; D013923:Thromboembolism / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D064417:Vitamin K Epoxide Reductases
chemical_list: D000925:Anticoagulants; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases; D000074:Acenocoumarol